SCHEMBL31200720

SCHEMBL31200720

Cc1cc(C)c(-c2ccc(N3C[C@@H]4[C@@H](C3)OCCN4C(=O)OC(C)(C)C)nn2)c(O)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IL1B P01584 7/20 0.37
NLRP3 Q96P20 4/20 0.37
SMARCA2 P51531 2/20 0.34
SMARCA4 P51532 2/20 0.34
PBRM1 Q86U86 2/20 0.34
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
DPP4 P27487 1/20 0.33
FLT3 P36888 1/20 0.32
TYRO3 Q06418 1/20 0.32
MERTK Q12866 1/20 0.32
GAS6 Q14393 1/20 0.32
GRM5 P41594 1/20 0.32
TNF P01375 1/20 0.32
ALDH1A1 P00352 1/20 0.32
RET P07949 1/20 0.31
LMNA P02545 2/20 0.31
NPSR1 Q6W5P4 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31200641 0.83 NLRP3 (0.44) IL1BNLRP3SMARCA2SMARCA4PBRM1
SCHEMBL31199533 0.80 NLRP3 (0.41) IL1BNLRP3TNF
SCHEMBL31200602 0.79 KMT2A (0.42) NR1H2NR1H3ALDH1A1LMNA
SCHEMBL31200513 0.77 IL1B (0.39) IL1BNLRP3TNF
SCHEMBL31200649 0.77 IL1B (0.39) IL1BNLRP3TNF
SCHEMBL31199368 0.75 HRH4 (0.42) IL1BNLRP3TNF
SCHEMBL31199417 0.75 HRH4 (0.42) IL1BNLRP3TNF
SCHEMBL31199686 0.74 IL1B (0.43) IL1BNLRP3TNFLMNA
SCHEMBL31199581 0.74 IL1B (0.43) IL1BNLRP3TNFLMNA
SCHEMBL31199415 0.73 NLRP3 (0.62) IL1BNLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680601-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES Sanofi (FR) 2026-01-21 EP disclosed
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-10-31 US disclosed
WO-2024188994-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES NLRP3, NOD1, NLRP1 IL1B 66/4885NLRP3 1/4885SMARCA2 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.